Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1404&sort=award_id
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_id", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=award_id", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=award_id", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1403&sort=award_id" }, "data": [ { "type": "Grant", "id": "9511", "attributes": { "award_id": "75N93019C00052-P00002-9999-2", "title": "COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2021-08-19", "award_amount": 969746, "principal_investigator": { "id": 25220, "first_name": "TED", "last_name": "ROSS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, SARS-COV-2 vaccines and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”).", "keywords": [ "2019-nCoV", "Animal Model", "Animals", "Contractor", "Contracts", "Coronavirus", "Elderly", "Human", "Immune", "Immune response", "Immunity", "Individual", "Mucous Membrane", "National Institute of Allergy and Infectious Disease", "Obesity", "Recording of previous events", "United States National Institutes of Health", "Vaccinated", "Vaccines", "anti-influenza", "coronavirus disease", "design", "high risk", "high risk population", "immunogenicity", "influenza virus vaccine", "innovation", "next generation", "novel vaccines", "pregnant", "programs", "response", "seasonal influenza", "standard of care", "universal influenza vaccine", "universal vaccine", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9512", "attributes": { "award_id": "75N93019C00052-P00002-9999-3", "title": "COVID supplement: A multi-site study seeking to study immune responses developed after infection with SARS-CoV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2021-08-19", "award_amount": 969655, "principal_investigator": { "id": 25220, "first_name": "TED", "last_name": "ROSS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Georgia University Research Foundation to support the National Cancer Institute's multi-site study seeking to determine if immune responses developed after confirmed infection with SARS-CoV-2.", "keywords": [ "2019-nCoV", "Foundations", "Immune response", "Infection", "National Cancer Institute", "Research", "Site", "Universities", "coronavirus disease" ], "approved": true } }, { "type": "Grant", "id": "9513", "attributes": { "award_id": "75N93019C00052-P00007-9999-3", "title": "COVID supplement: A multi-site study seeking to study immune responses developed after infection with SARS-CoV-2", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-10", "end_date": "2022-09-09", "award_amount": 1575867, "principal_investigator": { "id": 25220, "first_name": "TED", "last_name": "ROSS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Georgia University Research Foundation to support the National Cancer Institute's multi-site study seeking to determine if immune responses developed after confirmed infection with SARS-CoV-2.", "keywords": [ "2019-nCoV", "Foundations", "Immune response", "Infection", "National Cancer Institute", "Research", "Site", "Universities", "coronavirus disease" ], "approved": true } }, { "type": "Grant", "id": "9506", "attributes": { "award_id": "75N93019C00058-P00002-9999-2", "title": "Advanced Development of Medical Countermeasures for Infectious Diseases - COVID-19 Related Studies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-09", "end_date": "2020-12-31", "award_amount": 51953, "principal_investigator": { "id": 25213, "first_name": "GEORGE", "last_name": "PAINTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 265, "ror": "https://ror.org/03czfpz43", "name": "Emory University", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the advanced development of a promising candidate therapeutic. The research and development activities to be supported will allow the candidate therapeutic product to progress along the product development pathway, and include preclinical and IND enabling development activities, and clinical safety and efficacy assessment.", "keywords": [ "2019-nCoV", "Advanced Development", "COVID-19", "Clinical", "Communicable Diseases", "Development", "Influenza Therapeutic", "Pathway interactions", "Safety", "medical countermeasure", "pre-clinical", "product development", "research and development", "therapeutic candidate" ], "approved": true } }, { "type": "Grant", "id": "9531", "attributes": { "award_id": "75N93019C00062-P00003-9999-2", "title": "COVID Supplement B Cell Epitope Discovery and Mechanisms of Antibody Protection.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-16", "end_date": "2022-03-15", "award_amount": 1810144, "principal_investigator": { "id": 25238, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract supports the identification of human B cell epitopes derived from viral pathogens; such as Coronavirus, Dengue virus 4, Powassan virus, Chikungunya virus, and Venezuelan equine encephalitis virus, combined with basic studies to understand protective immunity mediated by antibodies, as well as pathological consequences of antibody responses.", "keywords": [ "Antibodies", "Antibody Response", "Antibody-mediated protection", "B-Lymphocyte Epitopes", "Chikungunya virus", "Coronavirus", "Dengue Virus", "Human", "Pathologic", "Powassan virus", "Support Contracts", "Venezuelan Equine Encephalitis Virus", "coronavirus disease", "pathogenic virus" ], "approved": true } }, { "type": "Grant", "id": "9517", "attributes": { "award_id": "75N93019C00065-P00002-9999-2", "title": "LARGE SCALE T CELL EPITOPE DISCOVERY - COVID Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2020-09-29", "award_amount": 650336, "principal_investigator": { "id": 25225, "first_name": "ALESSANDRO", "last_name": "SETTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The SARS-CoV-2 epitope Megapools (SARS-CoV-2 MPs) is used to study SARS-CoV-2 CD4 and CD8 specific T cell responses. The Megapool (MP) approach allows simultaneous testing of large number of epitopes. According to this approach large numbers of different epitopes are solubilized, pooled and re-lyophilized to avoid cell toxicity problems associated with high concentrations of DMSO typically encountered when single pre-solubilized epitopes are pooled. These MPs have been used for both CD4 and CD8 T cell epitope identification.", "keywords": [ "2019-nCoV", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "Cells", "Contracts", "Coronavirus", "Dimethyl Sulfoxide", "Epitopes", "Freeze Drying", "Ships", "T cell response", "T-Lymphocyte Epitopes", "Testing", "Toxic effect", "coronavirus disease" ], "approved": true } }, { "type": "Grant", "id": "9527", "attributes": { "award_id": "75N93019C00065-P00006-9999-2", "title": "LARGE SCALE T CELL EPITOPE DISCOVERY - COVID Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2021-09-29", "award_amount": 299928, "principal_investigator": { "id": 25233, "first_name": "STEPHEN", "last_name": "WILSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 777, "ror": "", "name": "LA JOLLA INSTITUTE FOR IMMUNOLOGY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The SARS-CoV-2 epitope Megapools (SARS-CoV-2 MPs) is used to study SARS-CoV-2 CD4 and CD8 specific T cell responses. The Megapool (MP) approach allows simultaneous testing of large number of epitopes. According to this approach large numbers of different epitopes are solubilized, pooled and re-lyophilized to avoid cell toxicity problems associated with high concentrations of DMSO typically encountered when single pre-solubilized epitopes are pooled. These MPs have been used for both CD4 and CD8 T cell epitope identification.", "keywords": [ "2019-nCoV", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "Cells", "Contracts", "Coronavirus", "Dimethyl Sulfoxide", "Epitopes", "Freeze Drying", "Ships", "T cell response", "T-Lymphocyte Epitopes", "Testing", "Toxic effect", "coronavirus disease" ], "approved": true } }, { "type": "Grant", "id": "9522", "attributes": { "award_id": "75N93019C00070-P00002-9999-2", "title": "IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) - SARS-CoV-2 RELATED RESEARCH", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-30", "end_date": "2022-09-29", "award_amount": 554910, "principal_investigator": { "id": 25229, "first_name": "KEVIN", "last_name": "URDAHL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 732, "ror": "https://ror.org/01njes783", "name": "Seattle Children's Hospital", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 732, "ror": "https://ror.org/01njes783", "name": "Seattle Children's Hospital", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this program is to establish an integrated multi-disciplinary team of highly collaborative investigators that will plan and conduct iterative, in-depth immunologic analyses of tissue-specific and systemic responses in small animals, non-human primates (NHPs), and humans to identify the key immune responses needed for protection against Mtb and to identify immunologic targets that can be used to improve TB vaccine strategies. This study will assess whether co-infection with SARS-CoV2 has a significant impact on innate immunity in study participants spanning the Mycobacterium tuberculosis (Mtb) infection spectrum.", "keywords": [ "2019-nCoV", "Animals", "Goals", "Human", "Immune", "Immune Targeting", "Immune response", "Immunologics", "Mycobacterium tuberculosis", "Natural Immunity", "Participant", "Research", "Research Personnel", "Tissues", "Tuberculosis", "Tuberculosis Vaccines", "co-infection", "improved", "multidisciplinary", "nonhuman primate", "programs", "response", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9477", "attributes": { "award_id": "75N93019C00073-P00001-9999-2", "title": "B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-16", "end_date": "2020-09-15", "award_amount": 2000000, "principal_investigator": { "id": 25191, "first_name": "BEN", "last_name": "DORANZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1835, "ror": "", "name": "INTEGRAL MOLECULAR", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1835, "ror": "", "name": "INTEGRAL MOLECULAR", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract supports the identification of human B cell epitopes derived from three viral pathogens; Zika, Marburg and Venezuelan equine encephalitis viruses, combined with basic studies to understand protective immunity mediated by antibodies. Milestones include 1) epitope identification; 2) epitope validation that must include in vitro evaluation using human samples; 3) submission of epitope data, computer software, and structural data to the Immune Epitope Database and Analysis Resource; and 4) studies to help understand the mechanisms of protection or pathogenesis elicited by antibodies associated with the newly identified epitopes. The Contractor will discover and characterize B cell epitopes on the Envelope (Env) proteins of Zika virus (ZIKV prM/E), Marburg virus (MARV GP), and Venezuelan equine encephalitis virus (VEEV E1/E2). They will generate new monoclonal antibodies (MAbs) by B cell cloning and next-generation sequencing using human clinical samples from both naturally infected and vaccinated individuals; Map the binding site of each Mab; Validate the functional relevance of each epitope to neutralize or, in the case of ZIKV MAbs, to enhance infectivity; and determine the mechanism of action of each Mab. Rapid mapping of SARS-CoV-2 specific antibodies using integral molecular' s high throughput epitope mapping platform (arrays of cells expressing S protein with point mutations at every amino acid position).", "keywords": [ "2019-nCoV", "Alanine", "Amino Acids", "Antibodies", "Antibody-Dependent Enhancement", "Antibody-mediated protection", "B-Lymphocyte Epitopes", "B-Lymphocytes", "Binding Sites", "Biochemical", "Cells", "Clinical", "Clone Cells", "Computer software", "Contractor", "Coronavirus", "Cryoelectron Microscopy", "Data", "Databases", "Epitope Mapping", "Epitopes", "Evaluation", "Family member", "Frankfurt-Marburg Syndrome Virus", "Human", "Immune", "Immune response", "In Vitro", "Individual", "Infection", "Maps", "Measures", "Molecular", "Molecular Conformation", "Monoclonal Antibodies", "Mutagenesis", "Pathogenesis", "Point Mutation", "Positioning Attribute", "Process", "Proteins", "Resources", "Role", "Sampling", "Scanning", "Shotguns", "Structure", "Support Contracts", "Testing", "Vaccinated", "Validation", "Venezuelan Equine Encephalitis Virus", "Viral Pathogenesis", "Virus", "ZIKA", "Zika Virus", "biophysical properties", "env Gene Products", "human subject", "in vivo", "next generation sequencing", "pathogenic virus", "protein complex", "structured data" ], "approved": true } }, { "type": "Grant", "id": "9478", "attributes": { "award_id": "75N93019C00073-P00006-9999-2", "title": "B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-09-16", "end_date": "2023-08-31", "award_amount": 1028905, "principal_investigator": { "id": 25191, "first_name": "BEN", "last_name": "DORANZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1835, "ror": "", "name": "INTEGRAL MOLECULAR", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1835, "ror": "", "name": "INTEGRAL MOLECULAR", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract supports the identification of human B cell epitopes derived from three viral pathogens; Zika, Marburg and Venezuelan equine encephalitis viruses, combined with basic studies to understand protective immunity mediated by antibodies. Milestones include 1) epitope identification; 2) epitope validation that must include in vitro evaluation using human samples; 3) submission of epitope data, computer software, and structural data to the Immune Epitope Database and Analysis Resource; and 4) studies to help understand the mechanisms of protection or pathogenesis elicited by antibodies associated with the newly identified epitopes. The Contractor will discover and characterize B cell epitopes on the Envelope (Env) proteins of Zika virus (ZIKV prM/E), Marburg virus (MARV GP), and Venezuelan equine encephalitis virus (VEEV E1/E2). They will generate new monoclonal antibodies (MAbs) by B cell cloning and next-generation sequencing using human clinical samples from both naturally infected and vaccinated individuals; Map the binding site of each Mab; Validate the functional relevance of each epitope to neutralize or, in the case of ZIKV MAbs, to enhance infectivity; and determine the mechanism of action of each Mab. Rapid mapping of SARS-CoV-2 specific antibodies using integral molecular' s high throughput epitope mapping platform (arrays of cells expressing S protein with point mutations at every amino acid position).", "keywords": [ "2019-nCoV", "Alanine", "Amino Acids", "Antibodies", "Antibody-Dependent Enhancement", "Antibody-mediated protection", "B-Lymphocyte Epitopes", "B-Lymphocytes", "Binding Sites", "Biochemical", "Cells", "Clinical", "Clone Cells", "Computer software", "Contractor", "Coronavirus", "Cryoelectron Microscopy", "Data", "Databases", "Epitope Mapping", "Epitopes", "Evaluation", "Family member", "Human", "Immune", "Immune response", "In Vitro", "Individual", "Infection", "Maps", "Marburgvirus", "Measures", "Molecular", "Molecular Conformation", "Monoclonal Antibodies", "Mutagenesis", "Pathogenesis", "Point Mutation", "Positioning Attribute", "Process", "Proteins", "Resources", "Role", "Sampling", "Scanning", "Shotguns", "Structure", "Support Contracts", "Testing", "Vaccinated", "Validation", "Venezuelan Equine Encephalitis Virus", "Viral Pathogenesis", "Virus", "ZIKA", "Zika Virus", "biophysical properties", "env Gene Products", "human subject", "in vivo", "next generation sequencing", "pathogenic virus", "protein complex" ], "approved": true } } ], "meta": { "pagination": { "page": 1404, "pages": 1424, "count": 14236 } } }